Interleukin-2-collagen chimeric protein which liberates interleukin-2 upon collagenolysis

被引:6
作者
Hayashi, M
Tomita, M
Yoshizato, K
机构
[1] Hiroshima Univ, Dev Biol Lab, Dept Sci Biol, Grad Sch Sci, Hiroshima 7398526, Japan
[2] Hiroshima Prefectural Inst Ind Sci & Technol, Japan Sci & Technol Corp, Hiroshima Tissue Regenerat Project, Hiroshima Prefectural Collaborat Reg Ent Adv Tech, Hiroshima 7390046, Japan
[3] Terumo Co Ltd, Ctr Res & Dev, Kanagawa 2590151, Japan
来源
PROTEIN ENGINEERING | 2002年 / 15卷 / 05期
关键词
chimeric protein; collagenase; drug delivery; fusion protein; type III collagen;
D O I
10.1093/protein/15.5.429
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interleukin-2 (IL-2) is a potent activator of cellular immunity and has been utilized as an immunotherapeutic agent. We stably immobilized human IL-2 to collagen by covalently binding it to the N-terminus of human type III collagen (3A1) as IL2-3A1 chimeric protein using recombinant technology. The present study was aimed at liberating IL-2 from the immobilized chimeric protein by treating the chimera with bacterial collagenase. These IL2-3A1 chimeras were synthesized in insect cells which had been infected with baculovirus vectors carrying IL2-3A1 cDNA. The IL2-3A1 protein produced was shown to be in a pepsin-resistant triple helical structure and exhibited IL-2 activity to a similar extent as IL-2 itself. IL2-3A1 could be immobilized on the surface of plastic dishes by incubating it in the dishes. The IL-2 region of the immobilized IL2-3A1 was liberated to culture media by collagenase treatment and this freed IL-2 stimulated the growth of lined T cells. Thus, IL2-3A1 chimeric protein could be utilized as an IL-2 deliverer whose T cell mitogenic activity can be liberated by a collagenolytic environment.
引用
收藏
页码:429 / 436
页数:8
相关论文
共 66 条
[11]   NOVEL DELIVERY SYSTEM FOR PROTEINS USING COLLAGEN AS A CARRIER MATERIAL - THE MINIPELLET [J].
FUJIOKA, K ;
TAKADA, Y ;
SATO, S ;
MIYATA, T .
JOURNAL OF CONTROLLED RELEASE, 1995, 33 (02) :307-315
[12]  
FUJIWARA T, 1990, CANCER RES, V50, P7003
[13]   AUGMENTATION OF ANTITUMOR EFFECT ON SYNGENEIC MURINE SOLID TUMORS BY AN INTERLEUKIN-2 SLOW DELIVERY SYSTEM, THE IL-2 MINI-PELLET [J].
FUJIWARA, T ;
SAKAGAMI, K ;
MATSUOKA, J ;
SHIOZAKI, S ;
FUJIOKA, K ;
TAKADA, Y ;
UCHIDA, S ;
ONODA, T ;
ORITA, K .
BIOTHERAPY, 1991, 3 (03) :203-209
[14]  
GILLIS S, 1978, J IMMUNOL, V120, P2027
[15]   LONG-TERM CULTURE OF TUMOR-SPECIFIC CYTOTOXIC T-CELLS [J].
GILLIS, S ;
SMITH, KA .
NATURE, 1977, 268 (5616) :154-156
[16]   SPECIFIC DEGRADATION OF COLLAGEN MOLECULE BY TADPOLE COLLAGENOLYTIC ENZYME [J].
GROSS, J ;
NAGAI, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1965, 54 (04) :1197-+
[17]   Production of EGF-collagen chimeric protein which shows the mitogenic activity [J].
Hayashi, M ;
Tomita, M ;
Yoshizato, K .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2001, 1528 (2-3) :187-195
[18]  
ISHIYAMA M, 1993, CHEM PHARM BULL, V41, P1118, DOI 10.1248/cpb.41.1118
[19]  
Kadler KE, 1996, BIOCHEM J, V316, P1
[20]   DELIVERY OF INTERLEUKIN-2 FOR IMMUNOTHERAPY [J].
KAPLAN, DR .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 662 (02) :315-323